Nicotine and the Myelin Mind

There is a molecule that has been smoked, chewed, snuffed, and metabolised by human beings for centuries, that is demonstrably addictive, increasingly shunned by society and yet simultaneously under serious investigation as a therapeutic agent in Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis.
The molecule is nicotine. And the reason it appears in all of these conditions, for better or for worse, is that it speaks directly to the myelination process.
This article is about what nicotine does when it arrives at the nervous system, stripped of everything else that accompanies it in tobacco, and what that pattern tells us about white matter and the conditions under which the self assembles or begins to fail.

I do not give medical advice, and nothing here should be read as a recommendation. I hold a PhD, not a medical degree.

The receptor that lives in white matter

Most people encounter nicotine as a story about neurons and addiction. But the receptor nicotine binds to is also expressed on oligodendrocyte precursor cells, the cells that mature into the oligodendrocytes that wrap axons in myelin. When nicotine arrives at these cells, it triggers the same kind of signal that drives myelination. The entire cholinergic system is embedded in the white matter, not incidentally but structurally.
The nervous system uses its own version of this signal to tell oligodendrocyte precursors to mature and myelinate. Nicotine, arriving from outside, speaks the same language. Whether that produces beneficial or destructive effects depends entirely on the cellular context in which the signal lands.

Parkinson’s disease: fifty shades of grey

More than fifty epidemiological studies have confirmed that smokers have a significantly lower incidence of Parkinson’s disease than non-smokers. The relationship is dose-dependent, and it holds whether the tobacco is smoked, chewed, or taken as snuff. Animal model research supports nicotine as the relevant component, showing protective effects on the dopaminergic neurons of the substantia nigra and reductions in the movement side effects of long-term drug therapy.
The clinical reality has so far been more sobering. A rigorous randomised trial published in 2023 found that one year of transdermal nicotine treatment did not slow disease progression in early Parkinson’s disease.
The Myelin Mind reading of this gap is that the epidemiological protection may be operating decades before diagnosis, in the long prodromal years when the myelinated infrastructure of motor timing is still being maintained and when the signal to white matter is doing its quiet work. By the time Parkinson’s disease becomes clinically visible, the window may already have closed.

Alzheimer’s disease: if at first you succeed…

The most widely prescribed drugs for Alzheimer’s disease work by slowing the breakdown of acetylcholine in the brain. What researchers discovered in 2015 is that one of these drugs also promotes oligodendrocyte maturation and the expression of myelin-associated genes, and that this effect on white matter works through the same nicotinic receptor pathway.
This was not what the drug was designed to do. But it raises the possibility that some of what these medications accomplish in practice is being done in white matter rather than at synapses, and that the drug’s partial efficacy in Alzheimer’s disease may owe something to inadvertent support of the myelination process.

Multiple sclerosis: smokin…

In the standard animal model of MS, nicotine consistently reduces clinical symptoms, lessens inflammation, and g get try t thattttttt tryst t significantly less demyelination of white matter. It also promotes the generation of mature myelin-producing oligodendrocytes from the stem cell reserve of the spinal cord. The two effects together, reduced immune attack and enhanced remyelination response, are exactly what is needed clinically. The clinical evidence in MS patients remains thin, but the animal evidence is more coherent here than in any other condition

Glioblastoma: the same signal, the wrong cell

This is where the story reverses.
Glioblastoma is the most aggressive primary brain tumour in adults, arising from glial cells. Research shows that glioblastoma cells express the same nicotinic receptor subtypes that drive OPC maturation in healthy tissue, and that nicotine activates the same survival and proliferation signals in tumour cells that it activates protectively in neurons. In the context of a cancer cell, promoting survival and proliferation is not protection. It is the opposite. Studies suggest nicotine increases tumour cell proliferation and may contribute to resistance to treatment.
The same receptor, the same signal, landing in a different cellular context, producing the appropriate response for that context. The receptor is not good or evil. It is a receiver. What it does with the signal depends entirely on what kind of cell is holding it.
A note on a claim circulating online: there is a viral story claiming nicotine dissolves glioblastoma tumours in 72 hours. This has been directly fact-checked by medical researchers and found to be false. The peer-reviewed evidence points the other way.

The key and the lock

Nicotine is a molecule that fits a receptor the nervous system designed for its own purposes. What this pattern across four conditions suggests is that the therapeutic potential of nicotinic signalling is real and mechanistically grounded, but it is not a property of nicotine itself. It is a property of the target tissue. The molecule is not the medicine. The myelination process is the medicine.
Whether that process is being supported or subverted by the arriving signal depends entirely on what kind of cell is doing the listening.

Jack Parry is a philosopher, polyglot and biomedical animator at Swinburne University of Technology. He is the author of The Myelin Mind: The Genesis of Meaning.

Further Reading

The review of cholinergic signalling in myelinating glia, covering the expression of nicotinic receptors on oligodendrocyte precursors and implications for Alzheimer’s disease and multiple sclerosis:
Fields RD, Bhattacharyya BJ. Cholinergic signaling in myelination. Glia, 2017 https://onlinelibrary.wiley.com/doi/abs/10.1002/glia.23101
The 2015 discovery that donepezil, the most prescribed Alzheimer’s drug, promotes oligodendrocyte maturation and myelin gene expression through nicotinic acetylcholine receptors:
Imamura O et al. Nicotinic acetylcholine receptors mediate donepezil-induced oligodendrocyte differentiation. Journal of Neurochemistry, 2015 https://pubmed.ncbi.nlm.nih.gov/26315944/
The comprehensive review of nicotine’s neuroprotective effects in Parkinson’s disease, covering more than fifty epidemiological studies and the animal model evidence:
Quik M et al. Nicotine as a potential neuroprotective agent for Parkinson’s disease. Movement Disorders, 2012 https://pubmed.ncbi.nlm.nih.gov/22693036/
The 2023 randomised controlled trial of transdermal nicotine in early Parkinson’s disease, which found no slowing of disease progression after one year:
Transdermal Nicotine Treatment and Progression of Early Parkinson’s Disease. NEJM Evidence, 2023 https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200311
The animal model study showing nicotine reduces demyelination, suppresses inflammation, and promotes oligodendrocyte generation in experimental MS:
Gao J et al. Nicotine modulates neurogenesis in the central canal during EAE. Frontiers in Neuroscience, 2015 https://pmc.ncbi.nlm.nih.gov/articles/PMC4428965/
The cell biology study confirming that nicotine activates proliferative signalling in glioblastoma cells via nicotinic receptor subtypes, promoting tumour growth rather than dissolution:
Pelosi A et al. Choline and nicotine increase glioblastoma cell proliferation by binding and activating nicotinic receptors. Pharmacological Research, 2020 https://pubmed.ncbi.nlm.nih.gov/33276105/